Ariad Pharmaceuticals Inc. tumbled the most ever after U.S. regulators placed a hold on enrollment in all trials of the company’s approved cancer drug Iclusig because of blood clots among participants.
Doctors cheered last year when the U.S. gave its first approvals for drugs to combat obesity in more than a decade. Eight months later, the two treatments have yet to catch on with consumers or investors.
Vivus Inc., maker of the recently approved obesity drug Qsymia, sank the most in more than two years after the company reported a larger third-quarter loss than analysts expected and investors feared slow uptake of the medicine.
With the worst flu outbreak since 2009 gripping the U.S., vaccine makers are determined to do better next season. They’re developing powerful vaccines that hold the promise of cutting incidences of flu by the thousands.
The acquisition of Pharmasset Inc. at the highest valuation on record for a drug takeover is turning makers of hepatitis C therapies from Inhibitex Inc. to Achillion Pharmaceuticals Inc. into the next targets.